TII
8.3.2021 14:09:09 CET | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the appointment of international experts in the field of systems security to the Board of Advisors of its Secure Systems Research Centre (SSRC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005482/en/
Secure Systems Research Centre is one of the initial seven dedicated centres at TII and is among the few global centres of its kind to bring together experts to conduct groundbreaking research in the field of secure systems. The distinguished new Board have combined expertise in security and resilience relating to autonomous computing and will guide the efforts of the Centre’s research team in developing end-to-end solutions to protect cyber-physical and autonomous systems.
The Board of Advisors comprises:
Prof. Ernesto Damiani, Professor, Department of Electrical Engineering and Computer Science, Senior Director, Artificial Intelligence & Intelligent Systems Institute, Director of the Center for Cyber Physical Systems (C2PS), Khalifa University in the UAE, whose research interests include secure service-oriented architectures, privacy-preserving big data analytics and cyber-physical systems security.
Dr Hoda Alkhzaimi, Research Assistant Professor at New York University Abu Dhabi (NYUAD) and Director of the University’s Center of Cyber Security, who was associated with research and development posts in cybersecurity and cryptology. Her research interests include unmanned aerial vehicle (UAV) security, cryptology, cryptanalysis, and building security hardware and software components.
Dr Bushra Alblooshi, Head of Research and Innovation at Dubai Electronic Security Center (DESC), who is focused on researching cloud computing, cybersecurity, computer forensics and cryptography.
Prof. Inseok Hwang, Professor at the School of Aeronautics and Astronautics at Purdue University, who specialises in research on intelligent and high assurance autonomy for cyber-physical systems with applications to complex networked systems, such as multi-vehicle systems.
Prof. Dongyan Xu, Samuel D. Conte Professor of Computer Science at Purdue University, specialises in research focused on cyber and cyber-physical security.
Prof. Taesoo Kim is Associate Professor at the School of Computer Science at the Georgia Institute of Technology, and his research interests span systems security architecture and design, threat intelligence, internet infrastructure and operating systems, machine learning, and programming languages.
Prof. Wenke Lee is Professor of Computer Science and John P. Imlay Jr. Chair, College of Computing at the Georgia Institute of Technology, and is one of the most prolific and influential cybersecurity researchers in the world. His research specialty is systems and network security, applied cryptography and machine learning.
Dr Harry Edelman is CEO of architectural consultancy Edelman Group and co-founder of AIDOMUS, a machine learning and IoT-based startup initiative for smart urban services. His work has focused on various aspects of integrated urban developments, including smart urban energy design and mobility.
Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre, said: “The Centre combines fundamental and applied research to set new standards and act as a catalyst to transform problems into solutions. The goal of the research team is to create new technologies for the development of end-to-end security and resilience in cyber-physical and autonomous systems.”
Research in security and resilience in cyber-physical and autonomous systems will ultimately lead to groundbreaking efforts in ensuring the safety and economic prosperity of our communities. The Board of Advisors will guide the expert SSRC researchers in carrying out such cutting-edge research while also creating new opportunities to train aspiring young UAE nationals in these significant fields.
For more information about Secure Systems Research Centre (SSRC), visit tii.ae/securesystems
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005482/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom